Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
BSX Boston Scientific
48.070+0.530+1.11%
Close
02/02 16:00 ET
48.280+0.210+0.44%
Post Mkt Price 02/02 16:27 ET
High
48.190
Open
47.650
Turnover
594.87M
Low
47.100
Pre Close
47.540
Volume
12.43M
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Boston Scientific Corp. Stock Rises Thursday, Still Underperforms Market
This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Boston Scientific Corp. (BSX) rose 1.11% to $48.07 Thursday, on what proved to be an all-ar
Boston Scientific Hit With $42M Verdict in Drug-eluting Stents IP Case
8 Analysts Have This to Say About Boston Scientific
Boston Scientific (NYSE:BSX) has observed the following analyst ratings within the last quarter: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings52100Last 30D210001M Ago010002M A
Needham Raises Price Target on Boston Scientific to $53 From $48, Maintains Buy Rating
09:22 AM EST, 02/02/2023 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Boston Scientific Is Maintained at Overweight by JP Morgan
Boston Scientific Price Target Raised to $55.00/Share From $48.00 by JP Morgan
Analysts Have Conflicting Sentiments on These Healthcare Companies: Align Tech (ALGN), Boston Scientific (BSX) and Evelo Biosciences (EVLO)
Boston Scientific Price Target Raised to $56.00/Share From $54.00 by Raymond James
Boston Scientific Is Maintained at Strong Buy by Raymond James
Raymond James Reaffirms Their Buy Rating on Boston Scientific (BSX)
Company Overview
More
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment consists of technologies for diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979, and is headquartered in Marlborough, MA.
CEO： Mr. Michael F. Mahoney
Market： NYSE
Listing Date： 05/18/1992
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet